Ko-Valodip's tablets are shown for treatment of essential hypertensia at adult patients whose arterial blood pressure is properly controlled by a combination of an amlodipin, a valsartan and a hydrochlorothiazide and who use three separate medicaments or two drugs, one of which is combined.

Structure

Active ingredient: amlodipin in the form of an amlodipin besilat, valsartan, a hydrochlorothiazide;

1 tablet, coated, contains 5 mg of an amlodipin in the form of an amlodipin besilat, 160 mg of a valsartan and 12.5 mg of a hydrochlorothiazide or 10 mg of an amlodipin in the form of an amlodipin besilat, 160 mg of a valsartan and 12.5 mg of a hydrochlorothiazide, or 10 mg of an amlodipin in the form of an amlodipin besilat, 160 mg of a valsartan and 25 mg of a hydrochlorothiazide;

Excipients: cellulose microcrystalline (type 200), mannitol, magnesium stearate, sodium of a kroskarmelloz, K 25 povidone, silicon dioxide colloidal, sodium lauryl sulfate;

Film cover: polyvinyl alcohol, a macrogoal 3350, the titan dioxide (E 171), talc, iron oxide yellow (E 172) (only for dosing of 10 mg / 160 mg / 25 mg), ferrous oxide red (E 172) (only for dosing of 10 mg / 160 mg / 12.5 mg).

Contraindication

• Hypersensitivity to the active ingredients, other streptocides derivative of dihydropyridine or to excipient.
• Pregnancy or planning of pregnancy.
• Abnormal liver function, biliary cirrhosis or cholestasia.
• Heavy renal failures (the glomerular filtration rate (GFR) <30 ml/min. / 1.73 m ² ), an anury and also stay on dialysis.
• Simultaneous use with the means containing aliskiren, to patients with diabetes or with renal failures (SKF <60 ml/min. / 1.73 m ² ).
• Refractory hypopotassemia, hyponatremia, hypercalcemia, symptomatic hyperuricemia.
• Heavy hypotension.
• Shock (including cardiogenic shock).
• Obstruction of an output path of a left ventricle (for example hypertrophic subaortic stenosis and stenosis of an aorta of heavy degree).
• Hemodynamically unstable heart failure after an acute myocardial infarction.

Route of administration

can be applied irrespective of meal. It is necessary to swallow of tablets entirely, washing down with water, at the same time day, it is desirable in the morning.

Feature of use

Pregnant

It is contraindicated.

Children

Are not present the corresponding use of Ko-Valodip to children aged up to 18 years for the indication essential hypertensia.

Drivers

With care.

Overdose

Is not present data on medicament overdose amlodipin/valsartan/gidrokhlorotiazid. The main symptom of overdose - the profound arterial hypotension with dizziness is possible. The overdose of an amlodipin can lead to the expressed vazodilatation of peripheral vessels and, perhaps, reflex tachycardia. It was reported about the profound and potential prolonged system hypotension, including shock with a lethal outcome at use of an amlodipin.

Side effects

Amlodipin/valsartan/hydrokhlorotiazid

• from metabolism and food: anorexia, hypercalcemia, lipidemia, hyperuricemia, hypopotassemia, hyponatremia;
• from mentality: insomnia/sleep disorder;
• from nervous system: an incoordination, dizziness, dizziness postural, dizziness at a tension, a dysgeusia, a headache, a lethargy, paresthesia, peripheral neuropathy, neuropathy, drowsiness, a syncope;
• from an organ of sight: disorder of vision;
• from an organ of hearing: vertigo;
• from heart: tachycardia;
• from the vascular system: arterial hypotension, orthostatic hypotension, phlebitis, thrombophlebitis;
• from a respiratory path, bodies of mediastinum and a thorax: cough, dispnoe, irritation of a throat;
• from a digestive tract: abdominal discomfort, pain in an upper part of a stomach, an unpleasant smell at breath, diarrhea, dryness in a mouth, dyspepsia, nausea, vomiting;
• from skin and its derivatives: hyperhidrosis, itching;
• from a skeletal and muscular system and connective tissue: dorsodynia, swelling of joints, spasms of muscles, muscle weakness, myalgia, extremity pain;
• from kidneys and an urinary system: increase in level of creatinine in blood plasma, a pollakiuria, OPN;
• from a reproductive system: impotence;
• general disturbances: abasia, disturbance of gait, asthenia, discomfort, indisposition, weakness, not cardial thorax pain, hypostases;
• inspection: increase in level of urea nitrogen, increase in level of uric acid in blood, decrease in level of potassium in blood plasma, increase in body weight.

Research of interaction of the combined medicament amlodipina/valsartana/gidrokhlorotiazida with other medicines was not conducted by

.

to

Storage conditions

For medicine special storage conditions. To store out of children's reach.

Expiration date - 2 years.